<?xml version="1.0" encoding="UTF-8"?>
<abstract id="bjh15459-abs-0001">
 <title>Summary</title>
 <p>In the Medical Research Council (
  <styled-content style="fixed-case">MRC</styled-content>) Myeloma 
  <styled-content style="fixed-case">IX</styled-content> trial (
  <styled-content style="fixed-case">ISRCTN</styled-content>684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (
  <styled-content style="fixed-case">CVAD</styled-content>) or cyclophosphamide, thalidomide and dexamethasone (
  <styled-content style="fixed-case">CTD</styled-content>) followed by autologous stem cell transplant (
  <styled-content style="fixed-case">ASCT</styled-content>) in the intensive pathway; attenuated 
  <styled-content style="fixed-case">CTD</styled-content> or melphalan and prednisolone (
  <styled-content style="fixed-case">MP</styled-content>) in the non‐intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (
  <styled-content style="fixed-case">EORTC</styled-content>) quality of life (QoL) questionnaires, 
  <styled-content style="fixed-case">QLQ</styled-content>‐C30 and 
  <styled-content style="fixed-case">QLQ</styled-content>‐
  <styled-content style="fixed-case">MY</styled-content>24, were administered at baseline, 3, 6 and 12 months and annually thereafter, enabling the effect of sequential treatment on patient‐reported health‐related QoL (
  <styled-content style="fixed-case">HR</styled-content>‐QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12 months that were compared using linear models. The intensive pathway showed significant differences in favour of 
  <styled-content style="fixed-case">CTD</styled-content> for Fatigue at 3 months and Physical Functioning at 12 months. The non‐intensive pathway and maintenance phase reported significant differences at 3 months; Pain (improved with attenuated 
  <styled-content style="fixed-case">CTD</styled-content>) and Global Health status/Quality of Life (improved with observation). The improved outcomes in 
  <styled-content style="fixed-case">MRC</styled-content> Myeloma 
  <styled-content style="fixed-case">IX</styled-content> were accompanied by some beneficial and few detrimental effects on 
  <styled-content style="fixed-case">HR</styled-content>‐QoL.
 </p>
</abstract>
